Combo Immunotherapy Ups Survival in Advanced Liver Cancer
Overall survival, but not progression-free survival, improved with tremelimumab plus durvalumab versus sorafenib for unresectable HCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.